CN105520923A - Application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to preparation of anti-tumor medicine - Google Patents
Application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to preparation of anti-tumor medicine Download PDFInfo
- Publication number
- CN105520923A CN105520923A CN201410571223.3A CN201410571223A CN105520923A CN 105520923 A CN105520923 A CN 105520923A CN 201410571223 A CN201410571223 A CN 201410571223A CN 105520923 A CN105520923 A CN 105520923A
- Authority
- CN
- China
- Prior art keywords
- cell
- tumor
- medicine
- cancer
- dihydroxykaur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of chemical engineering and the field of medicine, and relates to application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to preparation of anti-tumor medicine. The invention provides the application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to the preparation of the anti-tumor medicine. Tumor cells include liver cancer cells, lung adenocarcinoma cells and pancreatic cancer cells. The (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione belongs to a natural product, has the characteristics of low toxic and side effects, high bioavailability and stable property, and has the clinical use value. A small molecule compound is used as the novel anti-tumor medicine or an auxiliary ingredient of the anti-tumor medicine to be developed; the anti-tumor effect is obvious; green and environment-friendly effects are achieved; and a novel path and measure can be provided for treating and curing tumor.
Description
Technical field
The invention belongs to chemical field and field of medicaments, relate to (5 β, 7 α, 9 β, 10 α)-7,14-dihydroxy-16-alkene-3,15-diketone preparing the application in antitumor drug.
Background technology
(5 β, 7 α, 9 β, 10 α)-7,14-dihydroxy-16-alkene-3,15-diketone (in this application referred to as TT28) be important activity composition in Rabdosia rubescens.It is medicinal plants that Rabdosia rubescens has another name called Rabdosia rubescens, for Labiatae Herba Coriandri belongs to fork mutation of cracking rice, and herbaceos perennial, positive shade plant, slightly likes the moon, and winter resistance is strong; Generally high 30 ~ 130 centimetres, leaf is to life, and leaf-shrinkage, in the oval of band rib.8 ~ October blooms, 9 ~ November result.Because of plant leaf in winter condense into thin enter cicada's wings ice chip and gain the name.There is heat-clearing and toxic substances removing, anti-inflammatory analgetic, effect of invigorating blood circulation.Medicinal ingredient is volatile oil and Diterpenes, rubescensine A, B prime, C prime, D prime, penta element, pungent element and α mono-Amyrin.Chinese medicine is in order to treatment flu, headache, inflammation.(5 β, 7 α, 9 β, 10 α)-7,14-dihydroxy-16-alkene-3,15-diketone be active substance in Rabdosia rubescens, its essential information is as follows:
[English name] (5beta, 7alpha, 9beta, 10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione
[molecular formula] C20H28O4
[molecular weight] 332.43
[No. CAS] 79498-31-0
[detection mode] high performance liquid chromatography HPLC >=98%
[character] this product is white crystals
[effect and purposes] this product is used for assay.
[extract source] this product is labiate Rabdosia rubescens Rabdosiarubescens (Hamst.) C.Y.WuetHsuan, herb.
[pharmacological properties] density: 1.22g/cm
3.Fusing point: 513.4 DEG C of easy methanol, ethanol.
TT28 is the natural product taking from traditional important materials, and bioavailability is high, stable in properties, has Clinical practice and is worth.That studies the chemistry and biology of this compounds along with people gos deep into, and its molecular mechanism of action will be progressively clear and definite, and this will promote modifying for chemical structure and the structure activity study of this compounds further, and contribute to the medical value improving this compounds.
Summary of the invention
The object of this invention is to provide (5 β, 7 α, 9 β, 10 α)-7,14-new medicinal usage of dihydroxy-16-alkene-3,15-diketone (in this application referred to as TT28).
TT28 of the present invention, structural formula is as follows:
TT28 of the present invention is purchased from Yuan Mu bio tech ltd, Shanghai.
The invention provides TT28 and prepare the application in antitumor drug.Described tumor can be hepatocarcinoma, adenocarcinoma of lung, breast carcinoma, gastric cancer, cancer of pancreas, cervical cancer or leukemia.
Corresponding antitumor drug can be injection or tablet.
The invention provides a kind of method suppressing tumor cell in vitro to be bred, TT28 is added in the culture fluid of tumor cell.Described tumor cell can be hepatoma carcinoma cell, blood cell, cervical cancer cell, breast cancer cell or pancreatic cancer cell.The hepatoma carcinoma cell adopted in one embodiment of the present of invention is SK-HEP1, Focus and QGY.
CCK-8 test result shows, and TT28 can obvious antiproliferative effect, even causes death of neoplastic cells.Cell cycle result shows, and TT28 can promote apoptosis.
Generally speaking, the final concentration adding TT28 is 0.1-50 μM.Such as, 0.1-5 μM, 0.1-10 μM, 0.1-12 μM, 0.1-20 μM, 0.1-30 μM, 0.1-50 μM, 0.1-2 μM, 5-10 μM, 2-50 μM, 0.5-50 μM, 0.5-5 μM, 0.5-10 μM, 1-12 μM, 1-20 μM, 0.5-50 μM, 15-50 μM, 0.5-10 μM, 0.5-12 μM, 0.5-20 μM, 0.5-30 μM, 15-60 μM, etc.
Present invention also offers a kind of antitumor drug, the active component of described antitumor drug is TT28.Described tumor can be hepatocarcinoma, adenocarcinoma of lung, breast carcinoma, gastric cancer, cancer of pancreas, cervical cancer or leukemia.
Micromolecular compound of the present invention can adopt the preparation method of various routine to prepare.Such as, the method for artificial chemistry synthesis is adopted.
Utilize micromolecular compound of the present invention, by various conventional screening assays, can filter out, with TT28, interactional material occur, as receptor, inhibitor or antagonist etc.
The present invention and inhibitor, antagonist etc., when carrying out using (administration) on treating, can provide different effects.Usually, these materials can be formulated in nontoxic, inertia with in pharmaceutically acceptable aqueous carrier medium, wherein pH is about 5-8 usually, and preferably pH is about 6-8, and pH value can with being formulated the character of material and disease to be treated and changing to some extent.The pharmaceutical composition prepared can carry out administration by conventional route, comprising (but being not limited to): intramuscular, intraperitoneal, subcutaneous, Intradermal or topical.
For TT28 of the present invention, can by itself and suitable pharmaceutically acceptable carrier coupling.This kind of pharmaceutical composition contains the compound and pharmaceutically acceptable carrier or excipient for the treatment of effective dose.This kind of carrier comprises (but being not limited to): saline, buffer, glucose, water, glycerol, ethanol and combination thereof.Pharmaceutical preparation should match with administering mode.TT28 of the present invention can be made into injection form, such as, be prepared by conventional method with normal saline or the aqueous solution containing glucose and other adjuvant.The pharmaceutical composition of such as Tablet and Capsula and so on, is prepared by conventional method.Pharmaceutical composition such as injection, solution, Tablet and Capsula should aseptically manufacture.The dosage of active component is treatment effective dose, such as every day about 1 microgram/kg body weight-Yue 5 mg/kg body weight.In addition, TT28 of the present invention also can use together with other treatment agent.
When TT28 of the present invention is used as medicine, the TT28 for the treatment of effective dose can be applied to mammal, wherein this treatment effective dose is usually at least about 10 micrograms/kg body weight, and be in most of the cases no more than about 8 mg/kg body weight, preferably this dosage is about 10 micrograms/kg body weight-Yue 1 mg/kg body weight.Certainly, concrete dosage also should consider the factor such as route of administration, patient health situation, and these are all within skilled practitioners skill.
The invention provides TT28 and prepare the application in antitumor drug.TT28 is natural product, can the propagation of obvious inhibition tumor cell.Micromolecular compound of the present invention is developed as new antitumor drug or its auxiliary element, and tumor killing effect is obvious, environmental protection, provides a kind of new approach and means by for treatment and healing tumor.
Detailed description of the invention
Experimental technique:
1. cell recovery
1) from liquid nitrogen container, take out cryopreservation tube, directly drop in 37 DEG C of warm water, and shake makes it melt as early as possible frequently.
2) from 37 DEG C of water-baths, take out cryopreservation tube, with suction pipe sucking-off cell suspension, inject centrifuge tube and add more than 10 times culture fluid, low-speed centrifugal after mixing, abandons supernatant, then repeats to wash once with culture fluid.
3), after suitably diluting with culture fluid, inoculated and cultured bottle, be placed on 37 DEG C of incubator quiescent culture, next day changes culture fluid, continues to cultivate.Go down to posterity when being cultured to finite concentration.PANC-1 cell culture is in the DMEM high glucose medium containing 10%Gibico hyclone, SK-HEP1 and QGY cell culture, containing in the DMEM high glucose medium of 10% hyclone, contains 100U/ml penicillin and 100 μ g/ml streptomycins in culture medium.
2. passage is cultivated
Every day observation of cell growth situation, when cell grow in culture bottle about 90% converge time go down to posterity, about went down to posterity once every 2-4 days.One bottle goes down to posterity into three bottles, or a 25cm
2go down to posterity in a 75cm
2culture bottle in.Method:
1) with 1 × phosphate buffer washed cell once.
2) add the digestion of 2-3ml trypsinization liquid, be placed in 37 DEG C of incubator numbers minute.Pat Tissue Culture Flask with hands, make cell separation.
3) trypsinization is stopped with the suitable culture medium of the Gibico hyclone containing 10-15%.Cell is sub-packed in new culture bottle, continues to cultivate.
3. cell cryopreservation
1) get the cell tryptase protease digestion being cultured to exponential phase, to be collected in centrifuge tube and to count, centrifugal.
2) reject trypsin and old culture fluid, add the frozen culture fluid (containing 10%DMSO, 40%DMEM and 50%Gibico hyclone) configured, in cryopreserving liquid, the ultimate density of cell is 0.5-1 × 10
7/ ml.Blowing and beating gently with suction pipe makes cell even, and be then distributed in aseptic cryopreservation tube, often pipe adds 1-1.5ml.
3) cryopreservation tube is put into freezing storing box and put-80 DEG C of quick-freezings, move in liquid nitrogen container after 5 hours and preserve.
4. medicine prepares:
TT28 is dissolved in DMSO (dimethyl sulfoxide), and the mother solution being mixed with 100mM or 50mM is for subsequent use.
Embodiment 1MTS method measures TT28 to the growth inhibited effect of hepatoma carcinoma cell
SK-HEP1 cell (purchased from Chinese Academy of Sciences's cell bank) 3 × 10
3/ hole is seeded to 96 orifice plates, cultivate within 24 hours, make it adherent after add TT28 (purchased from Shanghai Pharmaceutical Inst., Chinese Academy of Sciences), if 6 Concentraton gradient, each concentration establishes 3 multiple holes.Cell at 37 DEG C, 5%CO
2cultivate after 72 hours under condition, outwell culture fluid, measure cell survival rate with MTS test kit (Promega company).
Method of testing is: cell serum-free medium is washed one time, adds the MTS chromophoric solution (add 2ml solution 1 and 100 μ l solution 2 in 10ml serum-free medium, fully mix) prepared in advance according to the amount of 100 μ l/well.Do not have the hole of cell to be set to this bottom outlet by one, the bias light in order to calibration solution absorbs.Cell is put into cell culture incubator and continues cultivation 2 ~ 4 hours, then absorbance value (reference wavelength 630-700nm is read by microplate reader, measure wavelength 490nm), calculate cell survival rate, to measure the numerical value of hole absorbance value/control wells absorbance value as cell survival rate.According to cell survival rate, calculate TT28 to the IC50 value of Sk-hep1 cell.
IC50 refers to the concentration of a suppressed half inhibitor.Here the concentration that SK-HEP1 cell quantity is a half TT28 of contrast is.The calculating of IC50 generally needs the dosage effect of mensuration more than 5, then obtains function calculating by curve fitting and obtain.
The IC50 value of result: TT28 to Sk-hep1 cell is 4.50 μMs.
Use the same method test QGY cell (purchased from Chinese Academy of Sciences's cell bank), and the IC50 value of result TT28 to QGY cell is about 23.10 μMs; Be about 2.90 μMs to the IC50 value of Focus cell, being about 11.00 μMs to the IC50 value of hep-G2 cell, is about 9.37 μMs to the IC50 value of SMMC-7721 cell.
Embodiment 2TT28 is to the growth inhibited effect of human leukemia cell
Cck-8 test kit (Japanese colleague's chemistry institute) is utilized to detect.
Step:
1) planted in 96 orifice plates uniformly by K562 cell (purchased from Chinese Academy of Sciences's cell bank), every porocyte number is 10
4individual.
2) treat adherent, dosing after spending the night, dosing (TT28 concentration is respectively 50,16.67,5.56,1.85,0.62 μMs), each concentration has 3 multiple holes.
3) cultivate 48 hours, complete medium is replaced to the mixture (10:1) of serum-free medium and CCK8, hatch 2 hours in 37 DEG C of incubators.
4) be measure wavelength with 450nm, take 650nm as contrast wavelength, in microplate reader, measure reading.
The IC50 value of result: TT28 to K562 cell is 2.49 μMs.
Embodiment 3TT28 is to the growth inhibited effect of human pancreatic cancer cell
TT28 is detected to the growth inhibited effect of human pancreatic cancer cell according to the method for embodiment 2.
Result shows, and the IC50 value of TT28 to human pancreatic cancer cell PANC-1 is 1.83 μMs.
Embodiment 4TT28 is to the growth inhibited effect of human lung adenocarcinoma cell
TT28 is detected to the growth inhibited effect of human lung adenocarcinoma cell according to the method for embodiment 2.
Result shows, and the IC50 value of TT28 to human A549 cell lines is 5.67 μMs.
Embodiment 5TT28 is to the growth inhibited effect of gastric carcinoma cells
TT28 is detected to the growth inhibited effect of gastric carcinoma cells according to the method for embodiment 2.
Result shows, and the IC50 value of TT28 to HGC cell is 2.86 μMs.
Embodiment 6TT28 is to the growth inhibited effect of human breast cancer cell
TT28 is detected to the growth inhibited effect of human breast cancer cell according to the method for embodiment 2.
Result shows, and the IC50 value of TT28 to human breast cancer cell line Bcap-37 is 3.36 μMs.
Embodiment 7TT28 is to the growth inhibited effect of human cervical carcinoma cell
TT28 is detected to the growth inhibited effect of human cervical carcinoma cell according to the method for embodiment 2.
Result shows, and the IC50 value of TT28 to human cervical carcinoma cell cervix uteri is 4.41 μMs.
The detection of embodiment 8 cell cycle
Get SMMC-7721 cell 3 × 105 cell and be inoculated in 60mm Tissue Culture Dish.After gradient drug treating, 37 DEG C of CO2 incubators cultivate 24h.Enter in centrifuge tube by cell culture fluid and cell harvesting, the centrifugal 10min of 1000rpm, abandons supernatant.1 × PBS of cell 2ml pre-cooling washes 1 time, and the centrifugal 10min of 1000rpm, abandons supernatant.With ethanol 4 DEG C of fixing 2h or the longer time of 70% pre-cooling.The centrifugal 10min of 1000rpm, carefully sops up supernatant.Resuspended with 500 μ lPI dye liquors, room temperature dark place dyeing 20min, by flow cytomery cell cycle situation of change after membrane filtration.
Result shows, and TT28 has significantly short apoptosis effect.
Claims (10)
1. (5 β, 7 α, 9 β, 10 α)-7,14-dihydroxy-16-alkene-3,15-diketone preparing the application in antitumor drug.
2. apply as claimed in claim 1, it is characterized in that, described tumor is hepatocarcinoma, adenocarcinoma of lung, breast carcinoma, gastric cancer, cancer of pancreas, cervical cancer or leukemia.
3. apply as claimed in claim 1, it is characterized in that, described antitumor drug is medicines resistant to liver cancer.
4. apply as claimed in claim 1, it is characterized in that, described antitumor drug is anti-pancreatic cancer drug.
5. apply as claimed in claim 1, it is characterized in that, described antitumor drug is Antilung gland cancer medicine.
6. apply as claimed in claim 1, it is characterized in that, described antitumor drug is Cycle Arrest medicine.
7. the method suppressing tumor cell in vitro to be bred, is characterized in that, is added by TT28 in the culture fluid of tumor cell; Described tumor cell is hepatoma carcinoma cell, breast cancer cell, stomach cancer cell, pancreatic cancer cell, cervical cancer cell, lung adenocarcinoma cell or pancreatic cancer cell.
8. method as claimed in claim 7, is characterized in that, add (5 β, 7 α, 9 β, 10 α)-7,14-the final concentration of dihydroxy-16-alkene-3,15-diketone be 0.1-50 μM.
9. a Cycle Arrest medicine, is characterized in that, the active component of described Cycle Arrest medicine is (5 β, 7 α, 9 β, 10 α)-7,14-dihydroxy-16-alkene-3,15-diketone.
10. the application of Cycle Arrest medicine according to claim 9, is characterized in that, the tumor that described medicine is suitable for is hepatocarcinoma, adenocarcinoma of lung, breast carcinoma, gastric cancer, cancer of pancreas, cervical cancer or leukemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410571223.3A CN105520923A (en) | 2014-10-23 | 2014-10-23 | Application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to preparation of anti-tumor medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410571223.3A CN105520923A (en) | 2014-10-23 | 2014-10-23 | Application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to preparation of anti-tumor medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105520923A true CN105520923A (en) | 2016-04-27 |
Family
ID=55763676
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410571223.3A Pending CN105520923A (en) | 2014-10-23 | 2014-10-23 | Application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to preparation of anti-tumor medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105520923A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455652A (en) * | 2009-01-05 | 2009-06-17 | 中国人民解放军第二军医大学 | Use of diterpenoids from Isodon japonica var.galaucocalyx in preparing anti-cancer medicine |
-
2014
- 2014-10-23 CN CN201410571223.3A patent/CN105520923A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101455652A (en) * | 2009-01-05 | 2009-06-17 | 中国人民解放军第二军医大学 | Use of diterpenoids from Isodon japonica var.galaucocalyx in preparing anti-cancer medicine |
Non-Patent Citations (5)
| Title |
|---|
| 嵇源源 等: "蓝萼甲、丙素细胞毒活性及其与Bcl-2蛋白关系的研究", 《抗感染药学》 * |
| 杨文华 等: "蓝萼甲素诱导K562细胞毒作用机制的初步研究", 《中国实验方剂学杂志》 * |
| 沈晓丹 等: "蓝萼甲素体外细胞毒活性研究", 《中华中医药学刊》 * |
| 王要军 等: "《现代恶性肿瘤的科学前沿》", 31 March 2007, 吉林科学技术出版社 * |
| 黄敬敬 等: "蓝萼甲素对宫颈癌HeLa细胞的作用及其相关机制研究", 《中国药理学通报》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102526073A (en) | Application of mogrol H9 for preparing antitumor drugs | |
| CN103202834A (en) | Applications of oridonin in the preparation of antineoplastic drugs | |
| CN103127049A (en) | Application of usnic acid in manufacturing antitumor drugs | |
| CN103127060A (en) | Application of chloranthus japonicus alcohol D in preparation of antitumor drugs | |
| CN103417536B (en) | The application in antitumor drug prepared by harmol | |
| CN103127061A (en) | Medicine application of chloranthus japonicus alcohol M | |
| CN103127063A (en) | Application of chloranthus japonicus alcohol F in preparation of antitumor drugs | |
| CN102397280B (en) | Application of 2 alpha-hydroxy protopanoxadiol medicine | |
| CN103127062A (en) | Application of 13'-acetyl silver grass alcohol C in manufacturing of antineoplastic drugs | |
| CN103099805A (en) | Application of isosteviol derivative H14 in preparation of antitumor medicaments | |
| CN105520923A (en) | Application of (5beta,7alpha,9beta,10alpha)-7,14-dihydroxykaur-16-ene-3,15-dione to preparation of anti-tumor medicine | |
| CN102366416B (en) | Pharmaceutical application of 12-dehydroxy-21-hydroxy protopanoxadiol | |
| CN105267201A (en) | Application of oridonin in preparing medicine for treating tumour | |
| CN103054851A (en) | Application of chloranthalactone C in preparation of anti-tumor medicament | |
| CN103083330B (en) | Application of solasodine in preparing antitumor medicines | |
| CN103083329B (en) | Application of picriafel-terrae 1 in anti-tumor drug preparation | |
| CN103417527A (en) | Medical uses of methyl (E)-3-[2-(4-hydroxy-3-methoxyphenyl)-3-hydroxymethyl-7-methoxy-2,3-dihydro-1-benzofuran-5-yl]-prop-2-enoate | |
| CN103127051A (en) | Application of curcumenol in anti-tumor drug preparation | |
| CN103127057A (en) | Application of fraxinellone in preparing of antineoplastic medicines | |
| CN103127039A (en) | Application of magnolol in preparation of antitumor drug | |
| CN102488677B (en) | Application of thelephora ganbajun in preparation of antitumor drugs | |
| CN103127103A (en) | Application of sophoridine in anti-tumor drug preparation | |
| CN104887651A (en) | Application of dendroflorin in preparation of antitumor drugs | |
| CN103127056A (en) | Application of psoromic acid in anti-tumor drug preparation | |
| CN103099804A (en) | Application of isosteviol lactone in preparation of antitumor medicaments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160427 |
|
| WD01 | Invention patent application deemed withdrawn after publication |